4
Changes in Ownership
Prelude Therapeutics Inc Filed Acc 0001209191-22-022524
EVP, Head of Chemistry acquired 36,062 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Combs Andrew EVP, Head of Chemistry | 2022-03-31 | Option exercise | +36,062 | $1.89 | $68,157 | 304,442 | D |
| Derivatives | |||||||
| Combs Andrew EVP, Head of Chemistry | 2022-04-01 | Option exercise · Employee Stock Option (right to buy) | −36,062 | 50,397 | D | ||
Loading xslF345X03/doc4.xml…